TapewireFind a company

organization · Reporting owner

MVA Investors, LLC

Disclosed activity across 8 companies

Tapewire entity
89263
SEC CIK
0001468223

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Mirati Therapeutics, Inc.MRTX · Entity 94908See remarksJanuary 23, 2024January 25, 2024
Rain Oncology Inc.RAIN · Entity 94695Director · 10% ownerApril 23, 2021April 27, 2021
Solid Biosciences Inc.SLDB · Entity 491510% ownerMarch 04, 2019March 06, 2019
Tango Therapeutics, Inc.TNGX · Entity 1497See remarksJune 28, 2024July 03, 2024
Tyra Biosciences, Inc.TYRA · Entity 4680See RemarksFebruary 06, 2024February 08, 2024
iTeos Therapeutics, Inc.ITOS · Entity 7596510% ownerJanuary 03, 2022January 05, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2024-01-23 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2024-01-23 · Disposition to issuer · Disposed 287,866 · Balance 0

F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").

F2: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2024-01-23 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2024-01-23 · Disposition to issuer · Disposed 203,754 · Balance 0

F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").

F4: These securities are owned directly by Lockend Five, LLC, a limited liability company owned soley by Mr. Dissanayake. Each reporting person other than Lockend Five, LLC and Mr. Dissanayake disclaims beneficial ownership of these securities.

Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2024-01-23 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 4 · 2024-01-23 · Disposition to issuer · Disposed 3,135,966 · Balance 0

F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").

F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.

Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2024-01-23 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 5 · 2024-01-23 · Disposition to issuer · Disposed 30,518 · Balance 0

F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").

F6: These securities are owned directly by Mr. Fuglesang. Each reporting person other than Mr. Fuglesang disclaims beneficial ownership of these securities.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2024-01-23 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2024-01-23 · Disposition to issuer · Disposed 3,201,440 · Balance 0

F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").

F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct0 Reported balance After 2024-01-23 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2024-01-23 · Disposition to issuer · Disposed 332,809 · Balance 0

F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein.

F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock.

F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00IndirectSee Footnote0 Reported balance After 2024-01-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2024-01-23 · Disposition to issuer · Disposed 3,578,036 · Balance 0

F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein.

F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock.

F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.

Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00IndirectSee Footnote0 Reported balance After 2024-01-23 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2024-01-23 · Disposition to issuer · Disposed 1,413,475 · Balance 0

F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein.

F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock.

F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.

Filing footnotes · ownership attribution and instrument terms

F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").

F2: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

F4: These securities are owned directly by Lockend Five, LLC, a limited liability company owned soley by Mr. Dissanayake. Each reporting person other than Lockend Five, LLC and Mr. Dissanayake disclaims beneficial ownership of these securities.

F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.

F6: These securities are owned directly by Mr. Fuglesang. Each reporting person other than Mr. Fuglesang disclaims beneficial ownership of these securities.

F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein.

F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock.

Rain Oncology Inc.

Report date April 23, 2021 · Filed April 27, 2021

Jointly reported with Davis Aaron I.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnote1,175,000 Last balance in matching sequence After 2021-04-27 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rows

Row 1 · 2021-04-23 · Purchase · Acquired 25,000 · Balance 25,000

F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, (iv) MVA Investors, LLC ("MVA Investors"), and (v) Joe Lewis (collectively, the "Boxer Group"), and indirectly by Boxer Management, Mr. Lewis and Mr. Davis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Row 2 · 2021-04-23 · Purchase · Acquired 125,000 · Balance 150,000

F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, (iv) MVA Investors, LLC ("MVA Investors"), and (v) Joe Lewis (collectively, the "Boxer Group"), and indirectly by Boxer Management, Mr. Lewis and Mr. Davis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Row 3 · 2021-04-27 · Purchase · Acquired 1,025,000 · Balance 1,175,000

F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, (iv) MVA Investors, LLC ("MVA Investors"), and (v) Joe Lewis (collectively, the "Boxer Group"), and indirectly by Boxer Management, Mr. Lewis and Mr. Davis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectSee Footnote0 Reported balance After 2021-04-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2021-04-27 · Conversion · Disposed 3,263,986 · Balance 0

F2: Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-1.0799 basis at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Pursuant to an Exchange Agreement, dated April 17, 2021, the shares of Series B Preferred Stock reported herein were exchanged for shares of Non-Voting Common Stock on a one-for-1.0799 basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer.

F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, (iv) MVA Investors, LLC ("MVA Investors"), and (v) Joe Lewis (collectively, the "Boxer Group"), and indirectly by Boxer Management, Mr. Lewis and Mr. Davis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Series B Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2021-04-27 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2021-04-27 · Conversion · Disposed 86,097 · Balance 0

F2: Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-1.0799 basis at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Pursuant to an Exchange Agreement, dated April 17, 2021, the shares of Series B Preferred Stock reported herein were exchanged for shares of Non-Voting Common Stock on a one-for-1.0799 basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer.

F3: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, and indirectly by Mr. Davis who is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Non-Voting Common StockSEC Table II · derivative / convertible securityIndirectSee Footnote3,022,489 Reported balance After 2021-04-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2021-04-27 · Conversion · Acquired 3,022,489 · Balance 3,022,489

F2: Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-1.0799 basis at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Pursuant to an Exchange Agreement, dated April 17, 2021, the shares of Series B Preferred Stock reported herein were exchanged for shares of Non-Voting Common Stock on a one-for-1.0799 basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer.

F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, (iv) MVA Investors, LLC ("MVA Investors"), and (v) Joe Lewis (collectively, the "Boxer Group"), and indirectly by Boxer Management, Mr. Lewis and Mr. Davis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Non-Voting Common StockSEC Table II · derivative / convertible securityDirect79,726 Reported balance After 2021-04-27 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2021-04-27 · Conversion · Acquired 79,726 · Balance 79,726

F2: Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-1.0799 basis at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Pursuant to an Exchange Agreement, dated April 17, 2021, the shares of Series B Preferred Stock reported herein were exchanged for shares of Non-Voting Common Stock on a one-for-1.0799 basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer.

F3: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, and indirectly by Mr. Davis who is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, (iv) MVA Investors, LLC ("MVA Investors"), and (v) Joe Lewis (collectively, the "Boxer Group"), and indirectly by Boxer Management, Mr. Lewis and Mr. Davis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

F2: Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-1.0799 basis at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Pursuant to an Exchange Agreement, dated April 17, 2021, the shares of Series B Preferred Stock reported herein were exchanged for shares of Non-Voting Common Stock on a one-for-1.0799 basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer.

F3: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, and indirectly by Mr. Davis who is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Solid Biosciences Inc.

Report date March 04, 2019 · Filed March 06, 2019

Jointly reported with Boxer Capital, LLC, Boxer Asset Management Inc., Braslyn Ltd., LEWIS JOSEPH

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect3,923,272 Reported balance Holding disclosure · report date 2019-03-04 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 3,923,272

F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis and (v) MVA Investors, LLC ("MVA Investors") (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect11,488 Reported balance Holding disclosure · report date 2019-03-04 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 11,488

F2: These securities are owned directly by Braslyn and indirectly by Joseph C. Lewis, who is the sole indirect owner of and controls Braslyn. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect30,210 Reported balance Holding disclosure · report date 2019-03-04 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 30,210

F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis and (v) MVA Investors, LLC ("MVA Investors") (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

F2: These securities are owned directly by Braslyn and indirectly by Joseph C. Lewis, who is the sole indirect owner of and controls Braslyn. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Tango Therapeutics, Inc.

Report date June 28, 2024 · Filed July 03, 2024

Jointly reported with Davis Aaron I.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect108,793 Last balance in matching sequence After 2024-07-02 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rows

Row 1 · 2024-06-28 · Sale · Disposed 29,000 · Balance 314,524

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.48 to $8.68, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

Row 2 · 2024-07-01 · Sale · Disposed 110,731 · Balance 203,793

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.75 to $9.00, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

Row 3 · 2024-07-02 · Sale · Disposed 95,000 · Balance 108,793

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.30 to $9.05, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.48 to $8.68, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.75 to $9.00, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.30 to $9.05, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Tyra Biosciences, Inc.

Report date February 06, 2024 · Filed February 08, 2024

Jointly reported with Boxer Capital, LLC, Boxer Asset Management Inc., LEWIS JOSEPH, Davis Aaron I.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnote85,939 Reported balance After 2024-02-06 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2024-02-06 · Grant · Acquired 63,412 · Balance 85,939

F1: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct705,280 Reported balance After 2024-02-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2024-02-06 · Grant · Acquired 705,280 · Balance 705,280

F3: These Warrants are exercisable immediately (subject to any applicable beneficial ownership limitation) and do not have an expiration date.

F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

Common StockSEC Table I · non-derivativeDirect6,448,359 Reported balance Holding disclosure · report date 2024-02-06 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 6,448,359

F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

F3: These Warrants are exercisable immediately (subject to any applicable beneficial ownership limitation) and do not have an expiration date.

iTeos Therapeutics, Inc.

Report date January 03, 2022 · Filed January 05, 2022

Jointly reported with Boxer Capital, LLC, Boxer Asset Management Inc., LEWIS JOSEPH, Davis Aaron I.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect3,912,113 Reported balance After 2022-01-03 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2022-01-03 · Sale · Disposed 432,903 · Balance 3,912,113

F3: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $47.4904 to $47.8617.

F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect3,872,632 Reported balance After 2022-01-03 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2022-01-03 · Sale · Disposed 39,481 · Balance 3,872,632

F4: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $49.2035 to $50.1716.

F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect3,855,459 Reported balance After 2022-01-03 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2022-01-03 · Sale · Disposed 17,173 · Balance 3,855,459

F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect48,890 Reported balance After 2022-01-03 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 4 · 2022-01-03 · Sale · Disposed 23,353 · Balance 48,890

F3: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $47.4904 to $47.8617.

F2: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group

Common StockSEC Table I · non-derivativeDirect47,208 Reported balance After 2022-01-03 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 5 · 2022-01-03 · Sale · Disposed 1,682 · Balance 47,208

F4: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $49.2035 to $50.1716.

F2: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group

Common StockSEC Table I · non-derivativeDirect46,477 Reported balance After 2022-01-03 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 6 · 2022-01-03 · Sale · Disposed 731 · Balance 46,477

F2: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group

Common StockSEC Table I · non-derivativeDirect3,767,405 Reported balance After 2022-01-04 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 7 · 2022-01-04 · Sale · Disposed 88,054 · Balance 3,767,405

F5: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $41.4811 to $42.1440.

F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect3,758,039 Reported balance After 2022-01-04 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 8 · 2022-01-04 · Sale · Disposed 9,366 · Balance 3,758,039

F6: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $42.6291 to $43.4221.

F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect3,724,742 Reported balance After 2022-01-04 transaction · row 9 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 9 · 2022-01-04 · Sale · Disposed 33,297 · Balance 3,724,742

F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect3,717,259 Reported balance After 2022-01-04 transaction · row 10 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 10 · 2022-01-04 · Sale · Disposed 7,483 · Balance 3,717,259

F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Common StockSEC Table I · non-derivativeDirect16,854 Reported balance After 2022-01-04 transaction · row 11 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 11 · 2022-01-04 · Sale · Disposed 29,623 · Balance 16,854

F5: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $41.4811 to $42.1440.

F2: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group

Common StockSEC Table I · non-derivativeDirect13,716 Reported balance After 2022-01-04 transaction · row 12 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 12 · 2022-01-04 · Sale · Disposed 3,138 · Balance 13,716

F6: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $42.6291 to $43.4221.

F2: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group

Common StockSEC Table I · non-derivativeDirect2,517 Reported balance After 2022-01-04 transaction · row 13 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 13 · 2022-01-04 · Sale · Disposed 11,199 · Balance 2,517

F2: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2022-01-04 transaction · row 14 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 14 · 2022-01-04 · Sale · Disposed 2,517 · Balance 0

F2: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group

Filing footnotes · ownership attribution and instrument terms

F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

F2: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group

F3: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $47.4904 to $47.8617.

F4: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $49.2035 to $50.1716.

F5: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $41.4811 to $42.1440.

F6: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $42.6291 to $43.4221.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

PMV Pharmaceuticals, Inc.

Report date September 25, 2020 · Filed September 29, 2020

Jointly reported with Boxer Capital, LLC, Boxer Asset Management Inc., LEWIS JOSEPH, Davis Aaron I.

Section 16 reporting ended · disclosed 2020-09-29. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,268,236 Last balance in matching sequence After 2020-09-29 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rows

Row 1 · 2020-09-25 · Purchase · Acquired 950,000 · Balance 950,000

F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein.

Row 2 · 2020-09-29 · Conversion · Acquired 586,099 · Balance 1,536,099

F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.

F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein.

Row 3 · 2020-09-29 · Conversion · Acquired 732,137 · Balance 2,268,236

F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.

F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee footnote60,837 Last balance in matching sequence After 2020-09-29 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 4 · 2020-09-29 · Conversion · Acquired 32,708 · Balance 32,708

F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.

F3: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Row 5 · 2020-09-29 · Conversion · Acquired 28,129 · Balance 60,837

F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.

F3: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Series C Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-09-29 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2020-09-29 · Conversion · Disposed 586,099 · Balance 0

F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.

F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein.

Series C Preferred StockSEC Table II · derivative / convertible securityIndirectSee footnote0 Reported balance After 2020-09-29 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2020-09-29 · Conversion · Disposed 32,708 · Balance 0

F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.

F3: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Series D Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-09-29 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2020-09-29 · Conversion · Disposed 732,137 · Balance 0

F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.

F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein.

Series D Preferred StockSEC Table II · derivative / convertible securityIndirectSee footnote0 Reported balance After 2020-09-29 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2020-09-29 · Conversion · Disposed 28,129 · Balance 0

F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.

F3: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein.

F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.

F3: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Pandion Therapeutics, Inc.

Report date July 21, 2020 · Filed July 21, 2020

Jointly reported with Boxer Capital, LLC, Boxer Asset Management Inc., Braslyn Ltd., LEWIS JOSEPH, Davis Aaron I.

Section 16 reporting ended · disclosed 2020-07-21. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect2,107,513 Last balance in matching sequence After 2020-07-21 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2020-07-21 · Conversion · Acquired 1,385,291 · Balance 1,385,291

F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Row 3 · 2020-07-21 · Purchase · Acquired 722,222 · Balance 2,107,513

F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee footnote23,622 Reported balance After 2020-07-21 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2020-07-21 · Conversion · Acquired 23,622 · Balance 23,622

F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Series B Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2020-07-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2020-07-21 · Conversion · Disposed 7,064,136 · Balance 0

F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Series B Preferred StockSEC Table II · derivative / convertible securityIndirectSee footnote0 Reported balance After 2020-07-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2020-07-21 · Conversion · Disposed 120,460 · Balance 0

F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 21, 2020 Filed Jul 21, 2020 19:49 UTC Pandion Therapeutics, Inc. PAND · Entity 11788 ConversionCommon Stock 23,622 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019894 · doc4.xml · nonDerivative · entry 2

Boxer Capital, LLC · CIK 0001465837 · 10% owner

Boxer Asset Management Inc. · CIK 0001465836 · 10% owner

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Davis Aaron I. · CIK 0001465914 · 10% owner

MVA Investors, LLC · CIK 0001468223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 23,622

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F3 · ownership.nature: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
July 21, 2020 Filed Jul 21, 2020 19:49 UTC Pandion Therapeutics, Inc. PAND · Entity 11788 ConversionCommon Stock 1,385,291 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-019894 · doc4.xml · nonDerivative · entry 1

Boxer Capital, LLC · CIK 0001465837 · 10% owner

Boxer Asset Management Inc. · CIK 0001465836 · 10% owner

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Davis Aaron I. · CIK 0001465914 · 10% owner

MVA Investors, LLC · CIK 0001468223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,385,291

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
July 11, 2019 Filed Jul 15, 2019 16:30 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 OtherCommon Stock 5,547 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-019615 · doc4.xml · nonDerivative · entry 1

MVA Investors, LLC · CIK 0001468223 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 253,338

F1 · kind: On July 11, 2019, MVA Investors, LLC ("MVA Investors") distributed 5,547 shares of the common stock of the issuer to one of its members on a pro rata basis for no consideration.

F2 · ownership.direct: These securities are owned directly by the reporting person, which has sole voting and dispositive power with respect to these securities. The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital"), (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) the reporting person, (v) Joe Lewis, (vi) Ivan M. Lieberburg, (vii) Aaron I. Davis, (viii) Neil Reisman, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
May 23, 2019 Filed May 23, 2019 21:21 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 OtherCommon Stock 48,169 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-014657 · doc4.xml · nonDerivative · entry 1

MVA Investors, LLC · CIK 0001468223 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 258,885

F1 · kind: On May 23, 2019, MVA Investors, LLC ("MVA Investors") distributed 48,169 shares of the common stock of the issuer to one of its members on a pro rata basis for no consideration.

F2 · ownership.direct: These securities are owned directly by the reporting person, which has sole voting and dispositive power with respect to these securities. The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital"), (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) the reporting person, (v) Joe Lewis, (vi) Ivan M. Lieberburg, (vii) Aaron I. Davis, (viii) Neil Reisman, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group). Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
April 04, 2019 Filed Apr 8, 2019 21:20 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 OtherCommon Stock 180,926 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-010290 · doc4.xml · nonDerivative · entry 1

MVA Investors, LLC · CIK 0001468223 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 307,054

F1 · kind: On April 4, 2019, MVA Investors, LLC ("MVA Investors") distributed 126,716 shares and 54,210 shares of the common stock of the issuer to Shehan B. Dissanayake and Neil Reisman, respectively, on a pro rata basis for no consideration.

F2 · ownership.direct: These securities are owned directly by the reporting person, which has sole voting and dispositive power with respect to these securities. The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital"), (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) the reporting person, (v) Tuesday Thirteen Inc., (vi) Joe Lewis, (vii) Rodney W. Lappe, (viii) Ivan M. Lieberburg, (ix) Aaron I. Davis, (x) Neil Reisman, (xi) Shehan B. Dissanayake, and (xii) Christopher Fuglesang (collectively, the "Boxer Group). Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
February 20, 2019 Filed Feb 22, 2019 16:39 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 OtherCommon Stock 6,695 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-004564 · doc4.xml · nonDerivative · entry 1

MVA Investors, LLC · CIK 0001468223 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 487,980

F1 · kind: On February 20, 2019, MVA Investors, LLC ("MVA Investors") distributed 6,695 shares of the common stock of the issuer to one of its members on a pro rata basis for no consideration.

F2 · ownership.direct: These securities are owned directly by the reporting person, which has sole voting and dispositive power with respect to these securities. The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital"), (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) the reporting person, (v) Tuesday Thirteen Inc., (vi) Joe Lewis, (vii) Rodney W. Lappe, (viii) Ivan M. Lieberburg, (ix) Aaron I. Davis, (x) Neil Reisman, (xi) Shehan B. Dissanayake, and (xii) Christopher Fuglesang (collectively, the "Boxer Group). Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
February 11, 2019 Filed Feb 13, 2019 16:23 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 OtherCommon Stock 18,955 $0.00 $0.00
Disclosure

SEC source: 0000899243-19-003425 · doc4.xml · nonDerivative · entry 1

MVA Investors, LLC · CIK 0001468223 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 494,675

F1 · kind: On February 11, 2019, MVA Investors, LLC ("MVA Investors") distributed 18,955 shares of the common stock of the issuer to one of its members on a pro rata basis for no consideration in connection with such member's withdrawal from MVA Investors.

F2 · ownership.direct: These securities are owned directly by the reporting person, which has sole voting and dispositive power with respect to these securities. The reporting person may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital"), (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) the reporting person, (v) Tuesday Thirteen Inc., (vi) Joe Lewis, (vii) Rodney W. Lappe, (viii) Ivan M. Lieberburg, (ix) Aaron I. Davis, (x) Neil Reisman, (xi) Shehan B. Dissanayake, and (xii) Christopher Fuglesang (collectively, the "Boxer Group). Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 03, 2017 Filed Oct 3, 2017 18:21 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 OtherWarrant (right to purchase) · Derivative 78,186 $0.00 Strike: $7.86 $0.00
Disclosure

SEC source: 0000899243-17-023345 · doc4.xml · derivative · entry 4

Boxer Capital, LLC · CIK 0001465837 · 10% owner

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Fuglesang Christopher · CIK 0001465835 · 10% owner

LAPPE RODNEY W · CIK 0001579826 · Director · 10% owner

LIEBERBURG IVAN M · CIK 0001266427 · 10% owner

Reisman Neil · CIK 0001465834 · Director · 10% owner

Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner

Davis Aaron I. · CIK 0001465914 · 10% owner

MVA Investors, LLC · CIK 0001468223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 78,186 shares

Expires 2017-11-21

Read SEC document
October 03, 2017 Filed Oct 3, 2017 18:21 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 OtherWarrant (right to purchase) · Derivative 189,780 $0.00 Strike: $7.86 $0.00
Disclosure

SEC source: 0000899243-17-023345 · doc4.xml · derivative · entry 3

Boxer Capital, LLC · CIK 0001465837 · 10% owner

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Fuglesang Christopher · CIK 0001465835 · 10% owner

LAPPE RODNEY W · CIK 0001579826 · Director · 10% owner

LIEBERBURG IVAN M · CIK 0001266427 · 10% owner

Reisman Neil · CIK 0001465834 · Director · 10% owner

Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner

Davis Aaron I. · CIK 0001465914 · 10% owner

MVA Investors, LLC · CIK 0001468223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 189,780 shares

Expires 2017-11-21

Read SEC document
October 03, 2017 Filed Oct 3, 2017 18:21 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 OtherCommon Stock 78,186 $7.86 $614,541.96
Disclosure

SEC source: 0000899243-17-023345 · doc4.xml · nonDerivative · entry 2

Boxer Capital, LLC · CIK 0001465837 · 10% owner

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Fuglesang Christopher · CIK 0001465835 · 10% owner

LAPPE RODNEY W · CIK 0001579826 · Director · 10% owner

LIEBERBURG IVAN M · CIK 0001266427 · 10% owner

Reisman Neil · CIK 0001465834 · Director · 10% owner

Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner

Davis Aaron I. · CIK 0001465914 · 10% owner

MVA Investors, LLC · CIK 0001468223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 513,630

F2 · ownership.direct: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each of Messrs. Fuglesang, Lieberburg, Reisman, Dissanayake and Davis is a member of MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
October 03, 2017 Filed Oct 3, 2017 18:21 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 OtherCommon Stock 189,780 $7.86 $1,491,670.80
Disclosure

SEC source: 0000899243-17-023345 · doc4.xml · nonDerivative · entry 1

Boxer Capital, LLC · CIK 0001465837 · 10% owner

Braslyn Ltd. · CIK 0001642355 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Fuglesang Christopher · CIK 0001465835 · 10% owner

LAPPE RODNEY W · CIK 0001579826 · Director · 10% owner

LIEBERBURG IVAN M · CIK 0001266427 · 10% owner

Reisman Neil · CIK 0001465834 · Director · 10% owner

Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner

Davis Aaron I. · CIK 0001465914 · 10% owner

MVA Investors, LLC · CIK 0001468223 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,227,774

F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors"), (iv) Braslyn Ltd., (v) Joe Lewis, (vi) Christopher Fuglesang, (vii) Rodney W. Lappe, (viii) Ivan M. Lieberburg, (ix) Neil Reisman, (x) Shehan B. Dissanayake, and (xi) Aaron I. Davis (collectively, the "Boxer Group"). Joseph C. Lewis is the sole indirect beneficial owner of and controls Braslyn Ltd.

Read SEC document
January 06, 2017 Filed Jan 10, 2017 17:00 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 PurchaseWarrant (right to purchase) · Derivative 51,047 $5.60 Strike: $0.00 $285,812.15
Disclosure

SEC source: 0000899243-17-000987 · doc4.xml · derivative · entry 9

Boxer Capital, LLC · CIK 0001465837 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Boxer Asset Management Inc. · CIK 0001465836 · 10% owner

MVA Investors, LLC · CIK 0001468223 · 10% owner

LAPPE RODNEY W · CIK 0001579826 · 10% owner

LIEBERBURG IVAN M · CIK 0001266427 · 10% owner

Davis Aaron I. · CIK 0001465914 · 10% owner

Reisman Neil · CIK 0001465834 · 10% owner

Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner

Fuglesang Christopher · CIK 0001465835 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,047

Underlying: Common Stock · 51,047 shares

Expires not disclosed

F9 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock.

F3 · ownership.direct: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each of Messrs. Fuglesang, Reisman, Lieberburg, Dissanayake and Davis is a member of MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
January 06, 2017 Filed Jan 10, 2017 17:00 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 PurchaseWarrant (right to purchase) · Derivative 2,341,786 $5.60 Strike: $0.00 $13,111,659.81
Disclosure

SEC source: 0000899243-17-000987 · doc4.xml · derivative · entry 8

Boxer Capital, LLC · CIK 0001465837 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Boxer Asset Management Inc. · CIK 0001465836 · 10% owner

MVA Investors, LLC · CIK 0001468223 · 10% owner

LAPPE RODNEY W · CIK 0001579826 · 10% owner

LIEBERBURG IVAN M · CIK 0001266427 · 10% owner

Davis Aaron I. · CIK 0001465914 · 10% owner

Reisman Neil · CIK 0001465834 · 10% owner

Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner

Fuglesang Christopher · CIK 0001465835 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,341,786

Underlying: Common Stock · 2,341,786 shares

Expires not disclosed

F9 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock.

F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, (iii) Boxer Asset Management Inc. ("Boxer Management"), (v) MVA Investors, LLC ("MVA Investors"), (vi) Joe Lewis, (vii) Rodney W. Lappe, (viii) Ivan M. Lieberburg, (ix) Aaron I. Davis, (x) Neil Reisman, (xi) Shehan B. Dissanayake, and (xii) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Boxer Management and Messrs.

F2 · ownership.direct: (Continued from Footnote 1) Lewis, Fuglesang, Reisman, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital. Each of Messrs. Fuglesang, Reisman, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
January 06, 2017 Filed Jan 10, 2017 17:00 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 PurchaseCommon Stock 6,104 $5.60 $34,182.40
Disclosure

SEC source: 0000899243-17-000987 · doc4.xml · nonDerivative · entry 2

Boxer Capital, LLC · CIK 0001465837 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Boxer Asset Management Inc. · CIK 0001465836 · 10% owner

MVA Investors, LLC · CIK 0001468223 · 10% owner

LAPPE RODNEY W · CIK 0001579826 · 10% owner

LIEBERBURG IVAN M · CIK 0001266427 · 10% owner

Davis Aaron I. · CIK 0001465914 · 10% owner

Reisman Neil · CIK 0001465834 · 10% owner

Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner

Fuglesang Christopher · CIK 0001465835 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 435,444

F3 · ownership.direct: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each of Messrs. Fuglesang, Reisman, Lieberburg, Dissanayake and Davis is a member of MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document
January 06, 2017 Filed Jan 10, 2017 17:00 UTC Mirati Therapeutics, Inc. MRTX · Entity 94908 PurchaseCommon Stock 280,059 $5.60 $1,568,330.40
Disclosure

SEC source: 0000899243-17-000987 · doc4.xml · nonDerivative · entry 1

Boxer Capital, LLC · CIK 0001465837 · 10% owner

LEWIS JOSEPH · CIK 0001015747 · 10% owner

Boxer Asset Management Inc. · CIK 0001465836 · 10% owner

MVA Investors, LLC · CIK 0001468223 · 10% owner

LAPPE RODNEY W · CIK 0001579826 · 10% owner

LIEBERBURG IVAN M · CIK 0001266427 · 10% owner

Davis Aaron I. · CIK 0001465914 · 10% owner

Reisman Neil · CIK 0001465834 · 10% owner

Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner

Fuglesang Christopher · CIK 0001465835 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,037,994

F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, (iii) Boxer Asset Management Inc. ("Boxer Management"), (v) MVA Investors, LLC ("MVA Investors"), (vi) Joe Lewis, (vii) Rodney W. Lappe, (viii) Ivan M. Lieberburg, (ix) Aaron I. Davis, (x) Neil Reisman, (xi) Shehan B. Dissanayake, and (xii) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Boxer Management and Messrs.

F2 · ownership.direct: (Continued from Footnote 1) Lewis, Fuglesang, Reisman, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital. Each of Messrs. Fuglesang, Reisman, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.